SYNCOMFSyncom Formulations (India) Ltd.

    Syncom Formulations (India) Q2 FY27 Results: Consolidated Net Profit ₹26.65 Crore on Total Income of ₹148 Crore

    • Earnings
    • Pharmaceuticals
    Two clear glass laboratory test tubes lying on a plain grey surface, one with a few dark specks on it.
    B.Lachner, via Wikimedia Commons (CC0). Illustrative image.

    Syncom Formulations (India) reported consolidated total income of ₹148.21 crore and net profit of ₹26.65 crore for the quarter ended 30 Sep 2026, and standalone total income of ₹142.70 crore and net profit of ₹25.40 crore. The results were approved by the board on 13 Nov 2026, the company said in a filing on 13 Nov 2026.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹148.21 crore, up 16.7% YoY and 11.1% QoQ
    • Net profit and EPS: ₹26.65 crore, up 60.6% YoY; basic EPS ₹0.28 against ₹0.18
    • Profit before tax: ₹36.03 crore, up 63.5% YoY and 11.7% QoQ
    • Finance costs: ₹0.41 crore, up 53.8% YoY

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹142.70 crore, up 12.7% YoY and 7.7% QoQ
    • Net profit and EPS: ₹25.40 crore, up 50.8% YoY; basic EPS ₹0.27 against ₹0.18
    • Other income: ₹6.04 crore, up 15.5% YoY but down 22.7% QoQ

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    148.21126.97+16.7%133.36+11.1%
    26.6516.60+60.6%24.85+7.3%
    EPS, basic (₹)0.280.18+55.6%0.26+7.7%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Consolidated net profit grew faster than income. Net profit rose 60.6% year on year to ₹26.65 crore, while total income rose 16.7% to ₹148.21 crore. Profit before tax rose 63.5%, and tax expense rose 72.5% to ₹9.37 crore, so the tax rate was 26.0% of profit before tax, up from the year-earlier level of about 24.7%.

    Other income is a small part of the result. At ₹6.07 crore it is 4.1% of total income and 16.8% of profit before tax. Finance costs of ₹0.41 crore are 0.3% of total income, so borrowing costs are a minor line in this quarter's figures.

    Consolidated net profit rose 7.3% from the June quarter, slower than total income's 11.1% rise. The filing gives no reason for the change in other income, which fell 22.5% from ₹7.83 crore in Q1 FY27.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    142.70126.67+12.7%132.48+7.7%
    25.4016.84+50.8%24.59+3.3%
    EPS, basic (₹)0.270.18+50.0%0.26+3.8%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Standalone net profit rose 50.8% year on year to ₹25.40 crore, faster than total income of ₹142.70 crore, which rose 12.7%. Revenue from operations grew 12.5%, slower than other income, which rose 15.5%.

    The gap between the two natures is small. Consolidated net profit of ₹26.65 crore is ₹1.25 crore above the standalone figure, and consolidated total income is ₹5.51 crore higher. The company has three wholly owned subsidiaries, named in the filing as Synmex Pharma Pvt. Ltd., Santd Biotech Pvt. Ltd. and Vincit Biotech International Pvt. Ltd.

    The auditors' limited review report on both sets of results concludes that nothing has come to their attention to suggest a material misstatement. The company says the report has no impact on the results, and the filing does not say what point in the auditors' report it refers to.

    Inference

    The filing reports standalone other equity of ₹371.64 crore at 30 Sep 2026, against ₹318.30 crore at 31 Mar 2026, and consolidated other equity of ₹375.84 crore against ₹320.99 crore. The filing does not give the reason for the rise in other equity.

    Borrowings on the standalone balance sheet rose to ₹15.52 crore from ₹68.13 lakh at 31 Mar 2026, and the filing does not state the reason or the terms of the borrowing.

    The company restated the previously reported basic and diluted EPS for the quarter and year ended 30 Sep 2025, with no change to any line item; the filing does not say why the EPS was restated.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Latest posts